CBD Life Sciences Inc. (CBDL) Announces 3.5 Billion Share Reduction From the Authorization
CBD Life Sciences (CBDL) has announced a significant reduction of 3.5 billion shares from its authorization, demonstrating its commitment to enhancing shareholder value. The company has also implemented a new quarterly stock repurchase program, committing to buy back 10% of its revenue in stock each quarter.
The company reports a remarkable 1405.46% revenue growth since February 2024, attributed to its expanding product line and strategic partnerships, including presence on Walmart Marketplace. CBDL's product portfolio includes 3000MG Pain Relief Cream and Delta 8 Gummies.
These initiatives aim to reduce dilution, increase stock value, and strengthen the company's financial position while building investor confidence through strategic financial management.
CBD Life Sciences (CBDL) ha annunciato una significativa riduzione di 3,5 miliardi di azioni dalla sua autorizzazione, dimostrando il suo impegno per valorizzare gli azionisti. L'azienda ha anche implementato un nuovo programma di riacquisto di azioni trimestrale, impegnandosi ad acquistare il 10% delle sue entrate in azioni ogni trimestre.
L'azienda riporta una notevole crescita dei ricavi del 1405,46% da febbraio 2024, attribuita alla sua espansione della linea di prodotti e alle partnership strategiche, inclusa la presenza su Walmart Marketplace. Il portfolio prodotti di CBDL include Crema per il dolore da 3000MG e Caramelle Delta 8.
Queste iniziative mirano a ridurre la diluizione, aumentare il valore delle azioni e rafforzare la posizione finanziaria dell'azienda, costruendo nel contempo la fiducia degli investitori attraverso una gestione finanziaria strategica.
CBD Life Sciences (CBDL) ha anunciado una reducción significativa de 3.5 mil millones de acciones de su autorización, demostrando su compromiso con el aumento del valor para los accionistas. La compañía también ha implementado un nuevo programa trimestral de recompra de acciones, comprometiéndose a recomprar el 10% de sus ingresos en acciones cada trimestre.
La compañía reporta un notable crecimiento en ingresos del 1405.46% desde febrero de 2024, atribuido a la expansión de su línea de productos y a asociaciones estratégicas, incluida su presencia en Walmart Marketplace. El portafolio de productos de CBDL incluye Crema para el dolor de 3000MG y Gominolas Delta 8.
Estas iniciativas tienen como objetivo reducir la dilución, aumentar el valor de las acciones y fortalecer la posición financiera de la compañía, generando además confianza entre los inversores a través de una gestión financiera estratégica.
CBD 생명과학(CBDL)는 주주 가치를 높이기 위한 약속을 보여주며 승인된 주식 35억 주를 대폭 줄였다고 발표했습니다. 이 회사는 또한 매 분기 수익의 10%에 해당하는 주식을 재매입하는 새로운 분기별 주식 재매입 프로그램을 시행했습니다.
회사는 2024년 2월 이후 1405.46%의 매출 성장을 보고하며, 이는 제품 라인 확장 및 전략적 파트너십, Walmart Marketplace에의 진출 덕분입니다. CBDL의 제품 포트폴리오는 3000MG 통증 완화 크림과 Delta 8 구미를 포함합니다.
이러한 이니셔티브는 희석을 줄이고 주식 가치를 증가시키며 회사의 재무 상태를 강화하는 동시에 전략적인 재무 관리를 통해 투자자 신뢰를 구축하는 것을 목표로 합니다.
CBD Life Sciences (CBDL) a annoncé une réduction significative de 3,5 milliards d'actions de son autorisation, démontrant son engagement à améliorer la valeur pour les actionnaires. L'entreprise a également mis en place un nouveau programme de rachat d'actions trimestriel, s'engageant à racheter 10% de ses revenus en actions chaque trimestre.
L'entreprise rapporte une remarquable croissance des revenus de 1405,46% depuis février 2024, attribuée à l'élargissement de sa gamme de produits et à des partenariats stratégiques, y compris sa présence sur Walmart Marketplace. Le portefeuille de produits de CBDL comprend une crème anti-douleur de 3000MG et des gummies Delta 8.
Ces initiatives visent à réduire la dilution, à augmenter la valeur des actions et à renforcer la position financière de l'entreprise tout en construisant la confiance des investisseurs grâce à une gestion financière stratégique.
CBD Life Sciences (CBDL) hat eine signifikante Reduzierung von 3,5 Milliarden Aktien aus ihrer Genehmigung angekündigt, was ihr Engagement zur Steigerung des Aktionärswerts demonstriert. Das Unternehmen hat auch ein neues vierteljährliches Aktienrückkaufprogramm eingeführt, bei dem es sich verpflichtet, jede Quartal 10% seines Umsatzes in Aktien zurückzukaufen.
Das Unternehmen berichtet von einem bemerkenswerten Umsatzwachstum von 1405,46% seit Februar 2024, das auf die Erweiterung seiner Produktlinie und strategische Partnerschaften, einschließlich der Präsenz auf dem Walmart Marketplace, zurückzuführen ist. Das Produktportfolio von CBDL umfasst eine 3000MG Schmerzcreme und Delta 8 Gummibärchen.
Diese Initiativen zielen darauf ab, die Verwässerung zu reduzieren, den Aktienwert zu steigern und die finanzielle Position des Unternehmens zu stärken, während sie gleichzeitig das Vertrauen der Investoren durch strategisches Finanzmanagement aufbauen.
- Significant 3.5 billion share reduction from authorization to reduce dilution
- Implementation of quarterly stock buyback program (10% of revenue)
- 1405.46% revenue growth since February 2024
- Strategic partnership with Walmart Marketplace
- None.
Demonstrating shareholder confidence, CBDL commits to repurchasing
SCOTTSDALE, AZ / ACCESSWIRE / December 18, 2024 / CBD Life Sciences Inc. (OTC Pink:CBDL), a leading innovator in the CBD and wellness industry, is thrilled to announce a significant milestone in its ongoing commitment to delivering shareholder value. The company has successfully reduced its authorized share count by a staggering 3.5 billion shares. This strategic move underscores CBDL's dedication to strengthening its financial position and enhancing shareholder equity.
This monumental share reduction marks a pivotal moment for CBDL as it continues to streamline its capital structure and build trust with investors. By decreasing the number of authorized shares, CBDL aims to reduce dilution, increase stock value, and solidify its reputation as a company that prioritizes its shareholders' interests. This is a clear signal to the market that CBDL is committed to fostering sustainable growth while putting its shareholders first.
Key Benefits of the Share Reduction Initiative:
Enhanced Stock Value: By significantly reducing authorized shares, CBDL positions itself to offer greater value to shareholders, reflecting positively on stock performance and market sentiment.
Increased Investor Confidence: Demonstrates CBDL's long-term commitment to aligning with shareholder goals and building a robust and transparent financial framework.
Strategic Financial Management: Signals a disciplined approach to capital management, paving the way for stronger financial performance and long-term profitability.
In addition to this bold initiative, CBDL has announced a groundbreaking new policy to repurchase
The share reduction comes on the heels of an impressive
CBDL's leadership continues to pave the way for an exciting future. The company's visionary approach and relentless focus on innovation, sustainability, and customer satisfaction have positioned it as a trailblazer in the wellness sector. The decision to reduce shares and repurchase stock underscores the confidence CBDL's management has in its strategic direction and its ability to deliver tangible results for investors.
As CBDL looks ahead, the company remains steadfast in its mission to revolutionize the CBD industry with cutting-edge products and a commitment to excellence. With a robust pipeline of initiatives, including new product launches and expanded retail partnerships, the future is brighter than ever for CBD Life Sciences Inc.
About CBD Life Sciences Inc. CBD Life Sciences Inc. (OTC: CBDL) is at the forefront of the CBD and wellness revolution. The company offers a diverse range of high-quality CBD-based products, leveraging advanced nanotechnology and sustainable practices to deliver superior solutions for consumers and businesses alike. With a focus on innovation and investor confidence, CBDL is redefining the future of wellness.
Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.
Contact Information:
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720
SOURCE: CBD Life Sciences Inc.
View the original press release on accesswire.com
FAQ
How many shares did CBDL reduce from its authorization in December 2024?
What is CBDL's new stock buyback commitment announced in December 2024?
What was CBDL's revenue growth percentage since February 2024?
Which major retail partnership does CBDL have for product distribution?
What are the main products in CBDL's current portfolio?
